✉ The Friday AI Brief: the week's 5 best AI stories, tools & comparisons — in your inbox every Friday morning.

Boltz logo

Boltz Raises $110 Million to Turn Its Open-Source Molecular Models Into Pharma’s Default Design Platform

Boltz, the MIT spinout whose open-source models became a default tool for biomolecular modeling, has raised a $110 million Series A led by Bessemer Venture Partners to scale the commercial platform it sells to the world’s biggest drugmakers. Why it matters: Boltz is testing whether open models plus paid usage can beat the proprietary AI pipelines pharma companies have spent billions building in-house.

November 18, 2026

What happened

Boltz announced the $110 million Series A on Wednesday, November 18. Bessemer led the round, with participation from existing backers Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures, and new investors including Greycroft, F-Prime Capital, Hummingbird and Benchling. The round follows a $28 million seed announced in January, less than a year after the company launched. Boltz did not disclose a valuation.

The company grew out of research at MIT’s CSAIL and Jameel Clinic, in Professor Regina Barzilay’s lab. Its three founders — CEO Gabriele Corso, Jeremy Wohlwend and Saro Passaro — were core developers of the original open-source Boltz models, which Bessemer says have passed 5 million downloads and are used by more than 100,000 scientists.

From open source to a paid platform

In June, Boltz launched its first proprietary models: BoltzMol-1 for small-molecule drug discovery and BoltzProt-1 for protein design, sold through Boltz Lab and an API that plugs into existing research workflows and AI agents such as Claude Code and Codex. The company says BoltzMol-1 produced confirmed hits against six of ten challenging targets while testing just 28 to 51 compounds per target.

The commercial models are now deployed at Pfizer, GSK, Takeda and Bristol Myers Squibb, among others, and Boltz says it has partnerships with six of the world’s 20 largest pharmaceutical companies. Usage is the growth story the round is priced on: the company reports that weekly molecular token consumption by paying customers has risen roughly 50-fold in the last four months.

Why it matters

Drug discovery’s AI race has mostly been a story of closed, captive pipelines — Isomorphic Labs’ $5 billion raise this week being the largest example. Boltz is running the opposite play: give the base models away, become the tool scientists already know, then charge by usage for the frontier versions, the way labs already budget for sequencing and reagents. The risk is equally clear: a funding round and fast-growing token counts are not evidence that the models produce medicines, and well-funded rivals are chasing the same customers. But with six top-20 pharma partnerships signed in its first year, Boltz has earned the right to be watched.

Frequently asked questions

Who led Boltz’s Series A?

Bessemer Venture Partners led the $110 million round, joined by existing backers including Andreessen Horowitz and new investors including Greycroft, F-Prime Capital and Benchling.

What does Boltz sell?

AI models for biomolecular modeling and molecular design — open-source models for structure prediction, plus commercial models (BoltzMol-1 and BoltzProt-1) offered through Boltz Lab and an API.

Which drug companies use Boltz?

Boltz says its commercial models are deployed at Pfizer, GSK, Takeda and Bristol Myers Squibb, and that it has partnerships with six of the world’s 20 largest pharmaceutical companies.

Sources: Bessemer Venture Partners, FirstWord Pharma, Endpoints News, a16z via StartupHub.ai

Leave a Comment

Your email address will not be published. Required fields are marked *

Get the 5 best AI tools every week

Top AI news, tools, and prompts — one short email. Free, unsubscribe anytime.

Run a newsletter of your own? Monetize and grow it with SparkLoop →

Scroll to Top